Skip to main content
. 2022 Dec 26;14:17588359221141307. doi: 10.1177/17588359221141307

Table 4.

Efficacy endpoint for the VEGFR-1 rs9582036.

Median (95% CI) Bevacizumab maintenance arm Observation maintenance arm
VEGFR-1 rs9582036 CC N = 14 CA + AA N = 146 p CC N = 16 CA + AA N = 138 p
TCD 22.4 (14.8–NR) 14.4 (11.7–17.1) 0.047 NR (9.5–NR) 15.7 (12.7–21.9) 0.079
OS 28.2 (18.1–42.8) 22.5 (18.6–24.6) 0.510 22.66 (17.2–NR) 22.1 (19.5–25.2) 0.097
PFS 9.4 (7.2–11.3) 9.2 (8.71–10.1) 0.59 9.3 (7.5–10.8) 9.10 (7.9–9.7) 0.785
First CFI (IQR) 4.6 (3.3–7.4) 4.14 (2.3–6.1) 0.303 3.15 (2.6–4.9) 4 (2.7–6.0) 0.493

CFI, chemotherapy-free interval; IQR, interquartile range; OS, overall survival; PFS, progression-free survival; TCD, tumor control duration; VEGFR, vascular endothelial growth factor receptor.